On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
This table lists many of the insurance plans that currently cover Otezla. Amgen Inc. continually works to expand the number and location of insurance plans that cover the cost of Otezla. If the insurance plan that you seek is not on this table, please contact Amgen Inc. to inquire if additional plans have recently been added.
The Otezla SupportPlus™ program offers multiple resources for you and your patients, including insurance and reimbursement support. Financial assistance options are available to patients who face a wide variety of insurance scenarios:
Click here to learn more about Otezla SupportPlus™ or contact an Amgen Inc. representative at +1 805-447-1000 to discuss which financial-assistance program may be appropriate for your patient.
The Resource Center provides information to help start your patients on Otezla, to verify their insurance benefits, and to support their treatment. The Resource Center provides downloadable materials and guidance such as the prescription start form, a form to obtain a letter of medical necessity, an application for financial assistance for patients, and educational materials for patients.
If you have questions related to pharmacy benefit management procedures, please contact Otezla Support Plus (1-844-4Otezla) 8AM-8PM ET, Monday –Friday.
Request a rep for more information if the insurance plan that you seek is not included.
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Warnings and Precautions
Use in Specific Populations